Bruker (BRKR)
(Delayed Data from NSDQ)
$63.32 USD
-0.05 (-0.08%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $63.32 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$63.32 USD
-0.05 (-0.08%)
Updated Sep 10, 2024 04:00 PM ET
After-Market: $63.32 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
Zacks News
Here's Why You Should Add Bruker (BRKR) to Your Portfolio Now
by Zacks Equity Research
Investor confidence in Bruker (BRKR) is at a high, thanks to solid prospects.
Bruker (BRKR) Is Up 2.98% in One Week: What You Should Know
by Zacks Equity Research
Does Bruker (BRKR) have what it takes to be a top stock pick for momentum investors? Let's find out.
Why the Earnings Surprise Streak Could Continue for Bruker (BRKR)
by Zacks Equity Research
Bruker (BRKR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Here is Why Growth Investors Should Buy Bruker (BRKR) Now
by Zacks Equity Research
Bruker (BRKR) possesses solid growth attributes, which could help it handily outperform the market.
Bruker (BRKR) Rides High on Strong Nano Sales, New Buyouts
by Zacks Equity Research
Bruker (BRKR) is reaping solid synergy benefits from the acquisitions of Anasys, JPK and Alicona.
Bruker Launches Luxendo TruLive3D Imager, Expands NANO Arm (Revised)
by Zacks Equity Research
Bruker's (BRKR) latest Luxendo TruLive3D Imager revolutionizes cell culture live imaging in natural environments.
Bruker Launches Luxendo TruLive3D Imager in Mass Spectrometry
by Zacks Equity Research
Bruker's (BRKR) Luxendo TruLive3D Imager revolutionizes cell culture live imaging in natural environment.
Bruker (BRKR) Beats Q3 Earnings Estimates, Ups EPS Guidance
by Zacks Equity Research
Bruker (BRKR) delivers robust third-quarter revenue growth, backed by strong segmental performances.
Bruker (BRKR) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Bruker (BRKR) delivered earnings and revenue surprises of 13.16% and 5.13%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Bruker (BRKR) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Bruker (BRKR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Bruker To Buy Freiberg Instruments' Magnettech EPR Business
by Zacks Equity Research
The Freiberg Instruments' Magnettech EPR business acquisition is expected to boost Bruker's (BRKR) BioSpin business by complementing its existing range of EPR offerings.
Bruker (BRKR) Enters Into Alliance With Murdoch University
by Zacks Equity Research
Bruker's (BRKR) collaboration with Murdoch University will support International Centre of Excellence in metabolic phenotyping.
Bruker (BRKR) Introduces the nanoIR3-s Broadband System
by Zacks Equity Research
The launch of the FTIR spectroscopy system complements Bruker's (BRKR) target to boost its portfolio of nanoIR products.
Bruker (BRKR) Releases JPK NanoWizard 4 XP Bio-AFM System
by Zacks Equity Research
With the launch of this new system, Bruker (BRKR) establishes a performance yardstick for atomic force microscopy in the field of life science research.
Bruker (BRKR) Down 7.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Bruker (BRKR) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Bruker (BRKR) Q2 Earnings Beat Estimates, Margins Expand
by Zacks Equity Research
Bruker (BRKR) registers strong year-over-year revenue growth across all segments and geographies.
Bruker (BRKR) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Bruker (BRKR) delivered earnings and revenue surprises of 6.45% and 2.71%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
Garmin's (GRMN) Q2 Earnings & Revenues Surpass Estimates
by Zacks Equity Research
Garmin's (GRMN) second-quarter results benefit from strong performance by its fitness, outdoor, marine and aviation segments.
Can Bruker (BRKR) Q2 Earnings See BioSpin's Growth Revival?
by Zacks Equity Research
Bruker (BRKR) expects BioSpin to bode well for better organic growth in Q2.
Is Bruker (BRKR) Outperforming Other Computer and Technology Stocks This Year?
by Zacks Equity Research
Is (BRKR) Outperforming Other Computer and Technology Stocks This Year?
Bruker (BRKR) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
Bruker (BRKR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Illumina (ILMN) Grows on Innovation & International Growth
by Zacks Equity Research
Illumina (ILMN) is benefiting from sturdy demand for sequencing and array systems as well as consumables and services.
NuVasive (NUVA) Launches Pulse Integrated Technology Platform
by Zacks Equity Research
The launch of this system is in sync with NuVasive's (NUVA) endeavor to deliver end-to-end solutions that offer predictable clinical and economic outcomes in spine surgery.
Boston Scientific's Global Growth Robust Amid Currency Woe
by Zacks Equity Research
Boston Scientific (BSX) is currently pinning hopes on a stronger performance in China, backed by the recent approval of SYNERGY in the country.
Has Bruker (BRKR) Outpaced Other Computer and Technology Stocks This Year?
by Zacks Equity Research
Is (BRKR) Outperforming Other Computer and Technology Stocks This Year?